Baminercept
As of the edition of 20 October 2026, Baminercept is a protein: stopped in 2015; acts on LTA, LTB and TNFSF14.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2015
- Kind
- Protein
- Registered trials
- 8, 5 stopped early
- Disease areas
- Immune system; Bones, joints and muscles; Skin and connective tissue; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route A because of this drug.
Companies on route A for this drug
In the product1 company-target row is on route A because of Baminercept.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 7 | 2 | 0 | 5 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biogen | Lead sponsor of trials | 2005 to now |